Loading
An anti-angiogenic pill makes immunotherapy work in endometrial cancers that would otherwise ignore it, at the cost of significant side effects.
Lenvatinib plus pembrolizumab is a combination pairing for mismatch repair-proficient endometrial cancer that has progressed after platinum chemotherapy. VEGFR inhibition by lenvatinib reduces immunosuppressive myeloid cells and normalises tumour vessels so that T cells can enter, turning a cancer that largely ignores PD-1 monotherapy into one that responds. In the phase 3 KEYNOTE-775 / Study 309 trial the combination improved overall survival compared with chemotherapy both in all comers and in the pMMR population, but dose reductions and discontinuations for toxicity were common. In the first-line setting LEAP-001 failed to beat chemotherapy, so the pairing lives in the second line. It is one instance of the broader pattern of PD-1 blockade plus VEGF inhibition.
Shares KEYNOTE-775 / Study 309, Lenvatinib, Pembrolizumab.
Shares VEGF / VEGFR, PD-1, Pembrolizumab.
Shares VEGF / VEGFR, PD-1, Pembrolizumab.
Shares Lenvatinib, Endometrial cancer.
Shares Lenvatinib, Pembrolizumab.
Shares Lenvatinib, Pembrolizumab.
Shares Lenvatinib, Pembrolizumab.